$PMHS
Polomar Health Services, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224046803 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $9.849K $0.00
YoY Change
Cost Of Revenue $985.00 $0.00
YoY Change
Gross Profit $8.864K $0.00
YoY Change
Gross Profit Margin 90.0%
Selling, General & Admin $268.0K $18.41K
YoY Change 279.33%
% of Gross Profit 3023.88%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $268.0K $18.40K
YoY Change 279.35%
Operating Profit -$259.2K -$18.40K
YoY Change 266.8%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$12.16K
YoY Change -67.56%
Pretax Income -$127.6K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$271.3K -$127.6K
YoY Change 150.9%
Net Earnings / Revenue -2754.93%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 27.66M shares 109.1M shares 109.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.00
YoY Change
Cash & Equivalents $16.20K $224.00
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change
Inventory $139.9K $3.459K
Prepaid Expenses
Receivables
Other Receivables $0.00
Total Short-Term Assets $156.1K $244.00
YoY Change 21.04% -99.91%
LONG-TERM ASSETS
Property, Plant & Equipment $87.73K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $19.04M $94.83K
YoY Change
Total Long-Term Assets $19.13M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $156.1K $244.00
Total Long-Term Assets $19.13M $0.00
Total Assets $19.29M $244.00
YoY Change 14853.79% -99.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.78K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $33.85K $0.00
YoY Change 620.19%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $953.8K $13.78K
YoY Change 6296.37% -81.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $23.62K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $953.8K $13.78K
Total Long-Term Liabilities $23.62K $0.00
Total Liabilities $977.4K $13.78K
YoY Change 6454.78% -81.55%
SHAREHOLDERS EQUITY
Retained Earnings -$2.192M -$1.398M
YoY Change 72.53% 42.42%
Common Stock $27.66K $109.1K
YoY Change -74.66% 1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.31M -$13.54K
YoY Change
Total Liabilities & Shareholders Equity $19.29M $244.00
YoY Change 14853.79% -99.91%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$271.3K -$127.6K
YoY Change 150.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.14K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.700K
YoY Change
NET CHANGE
Cash From Operating Activities -10.14K
Cash From Investing Activities
Cash From Financing Activities -4.700K
Net Change In Cash -14.84K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$10.14K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001265521
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 us-gaap Assets Current
AssetsCurrent
156105 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
85345 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-172163 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56555
dei Entity Registrant Name
EntityRegistrantName
Polomar Health Services, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-1006313
dei Entity Address Address Line1
EntityAddressAddressLine1
10940 Wilshire Blvd. Suite 1500
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
dei City Area Code
CityAreaCode
(213)
dei Local Phone Number
LocalPhoneNumber
616-0011
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27655560 shares
CY2024Q3 us-gaap Cash
Cash
16202 usd
CY2023Q4 us-gaap Cash
Cash
8808 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On September 3, 2023, the Board authorized the execution of a reverse split of the issued and outstanding shares of the Corporation’s common stock at a ratio of up to 1:2,000
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On March 2, 2023, FINRA approved a 1-for-2,000 reverse stock split of the Company’s common stock that was approved by the Company’s Board of Directors
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
usd
CY2023Q4 TRFE Leasehold Improvements
LeaseholdImprovements
usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2024Q3 TRFE Noncompete Agreement Net
NoncompeteAgreementNet
usd
CY2023Q4 TRFE Intellectual Property
IntellectualProperty
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
TRFE Increase Decrease In Security Deposit
IncreaseDecreaseInSecurityDeposit
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q3 us-gaap Inventory Net
InventoryNet
139903 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
3459 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
12267 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
41458 usd
CY2024Q3 TRFE Leasehold Improvements
LeaseholdImprovements
49435 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3163 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87730 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57469 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
81665 usd
CY2023Q4 TRFE Noncompete Agreement Net
NoncompeteAgreementNet
4167 usd
CY2024Q3 TRFE Intellectual Property
IntellectualProperty
18975000 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
9000 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
9000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19041469 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
94832 usd
CY2024Q3 us-gaap Assets
Assets
19285304 usd
CY2023Q4 us-gaap Assets
Assets
107099 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
86328 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
39464 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
833586 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
30507 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
33849 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
32484 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
953763 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
102455 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23620 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49180 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
23620 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
49180 usd
CY2024Q3 us-gaap Liabilities
Liabilities
977383 usd
CY2023Q4 us-gaap Liabilities
Liabilities
151635 usd
CY2023Q4 TRFE Members Deficit
MembersDeficit
140500 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27655560 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27655560 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
27656 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
109138 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20472638 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1275156 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2192373 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1569830 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
18307921 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-44536 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19285304 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107099 usd
CY2024Q3 us-gaap Revenues
Revenues
9849 usd
CY2023Q3 us-gaap Revenues
Revenues
21457 usd
us-gaap Revenues
Revenues
37954 usd
us-gaap Revenues
Revenues
24556 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
985 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1534 usd
us-gaap Cost Of Revenue
CostOfRevenue
16121 usd
us-gaap Cost Of Revenue
CostOfRevenue
2070 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
8864 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
19923 usd
us-gaap Gross Profit
GrossProfit
21833 usd
us-gaap Gross Profit
GrossProfit
22486 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
256349 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
147328 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
582119 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
341274 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11688 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7273 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
50098 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27507 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
268037 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
154601 usd
us-gaap Operating Expenses
OperatingExpenses
632217 usd
us-gaap Operating Expenses
OperatingExpenses
368781 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-259173 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-134678 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-610384 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-346295 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12160 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
37485 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12160 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
37485 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12160 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37485 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12160 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37485 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-271333 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-172163 usd
us-gaap Net Income Loss
NetIncomeLoss
-622544 usd
us-gaap Net Income Loss
NetIncomeLoss
-383780 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27655560 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109138049 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27655560 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109138049 shares
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
106000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
19182 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-44536 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-160468 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-205004 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-190742 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-395746 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-395746 usd
CY2024Q3 TRFE Stock Issued During Period Value Conversion Of Preferred Stock
StockIssuedDuringPeriodValueConversionOfPreferredStock
-500 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
19116000 usd
CY2024Q3 TRFE Stock Issued During Period Value Conversion Of Acquiree Interest
StockIssuedDuringPeriodValueConversionOfAcquireeInterest
-140500 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-271333 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
18307921 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
18307921 usd
us-gaap Net Income Loss
NetIncomeLoss
-622544 usd
us-gaap Net Income Loss
NetIncomeLoss
-383780 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
20000 usd
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
37432 usd
us-gaap Inventory Write Down
InventoryWriteDown
-136443 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7330 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5865 usd
TRFE Increase Decrease In Security Deposit
IncreaseDecreaseInSecurityDeposit
-9000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
46865 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5291 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-704792 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-314191 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90893 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90893 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-132000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-30507 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-183318 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
833586 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1392 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
439044 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
803079 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
257118 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7394 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-189073 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8808 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
225619 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16202 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36546 usd
us-gaap Interest Paid Net
InterestPaidNet
9128 usd
us-gaap Interest Paid Net
InterestPaidNet
495 usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2000-09-14
CY2022Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse split in which each shareholder was issued one common share in exchange for every two thousand common shares of their then-currently issued common stock
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
266157 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
266157 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 TRFE Intellectual Property
IntellectualProperty
18975000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zKbNWkDmtmD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zdAwXiN0ps0f">Use of estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Cash
Cash
16202 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2192373 usd
us-gaap Net Income Loss
NetIncomeLoss
-622544 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-704792 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares

Files In Submission

Name View Source Status
trfe-20240930.xsd Edgar Link pending
trfe-20240930_cal.xml Edgar Link unprocessable
trfe-20240930_def.xml Edgar Link unprocessable
trfe-20240930_lab.xml Edgar Link unprocessable
trfe-20240930_pre.xml Edgar Link unprocessable
0001493152-24-046803-index-headers.html Edgar Link pending
0001493152-24-046803-index.html Edgar Link pending
0001493152-24-046803.txt Edgar Link pending
0001493152-24-046803-xbrl.zip Edgar Link pending
ex14-1.htm Edgar Link pending
ex2-3.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed